Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion,” please visit: https://ibn.fm/P86ov Researchers are working to confront significant obstacles related to drug penetration, tumor targeting, therapeutic resistance and maintaining consistent intratumoral exposure.